Naylor Stuart 4

What Happened
Stuart Naylor, MeiraGTx's Chief Scientific Officer, Ophthalmology, sold a total of 27,659 shares of MGTX stock in open-market transactions on July 7, 2026, receiving aggregate proceeds of approximately $409,470. The filing shows two reported disposals: 2,547 shares at a weighted-average price of $13.86 (proceeds $35,301) and 25,112 shares at a weighted-average price of $14.90 (proceeds $374,169). These transactions are sales (not purchases) and therefore typically represent liquidity events rather than a bullish purchase signal.

Key Details

• Transaction date: 2026-07-07 (both sales) — reported on Form 4 filed 2026-07-07. No indication in the filing that it was late.
• Reported sales and proceeds: 2,547 shares @ $13.86 = $35,301; 25,112 shares @ $14.90 = $374,169; total 27,659 shares for ~$409,470.
• Price details/footnotes: the reported prices are weighted averages. The smaller block was sold at prices ranging $13.36–$14.31 (inclusive); the larger block at $14.47–$15.33 (inclusive). The reporting person will provide per-price share counts on request.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Notable: Sales were effected under a Rule 10b5-1 trading plan adopted Dec 9, 2025 (pre-arranged plan).

Context
Sales made under a 10b5-1 plan are generally pre-scheduled and used to limit claims of trading on non-public information; they are often routine liquidity actions rather than directional signals. For retail investors, purchases are usually more informative about insider conviction; this filing documents a planned sale and provides weighted-average and price-range details if you request the per-price breakdown.